Drug
Favezelimab Pembrolizumab
Favezelimab Pembrolizumab: highest development phase Phase 3, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| favezelimab/pembrolizumab NCT05064059 | Phase 3 | Colorectal Cancer |
Latest
No recent events.
Follow Favezelimab Pembrolizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.